F120 - Dermatologic Side Effects of Anticancer Drugs in 2019: What You Need to Know
Monday, March 4; 9:00 AM - 11:00 AM
Following this course, the attendee should be able to:
- Recognize the impact on quality of life and clinical characteristics of dermatologic diverse events to novel cancer therapies.
- Describe the mechanisms involved in dermatologic adverse events to
novel cancer therapies.
- Discuss novel interventions towards dermatologic adverse events in cancer patients.
This session is directed towards dermatologists involved in the care of patients that are being treated with novel agents including targeted therapies and immune checkpoint inhibitors that have revolutionized cancer care. The session will include mechanisms to prevent and treat these untoward events, in order to maintain quality of life and consistent dosing of cancer therapies. In addition, strategies to prevent chemotherapy-induced alopecia will be described, which have increased the awareness of skin, hair, and nail disorders in oncology, and place dermatologists as an integral part of comprehensive cancer care.
- Kwong, Bernice, MD: Genentech, Inc. – C(Fees);
- Lacouture, Mario E., MD: AbbVie – C(H); ADC Therapeutics – C(H); Adgero Biopharmaceuticals Holdings, Inc. – C(H); Astellas Pharma US, Inc – C(H); Celldex – C(H); Galderma Research & Development, LLC – C(H); Harborside – O(Fees); Helsinn Healthcare – C(H); Johnson and Johnson – C(H); Lindiskin – C(H); Menlo Therapeutics – C(H); Merck & Co., Inc – C(H); Novartis – C(H); Novocure – C(H); Wiley & Sons, Inc. – O(Fees);
- Larocca, Cecilia, MD: no financial relationships exist with commercial interests.
- van den Hurk, Corina, PhD: Dignitana – I(Grants/Research Funding); Paxman – I(Grants/Research Funding), SP(OB);
Dr. Larocca / Treatments for Solid Tumors
Dr. Kwong / Treatments for Hematologic Cancers
Dr. Lacouture / Immune Checkpoint Inhibitors
van den Hurk / Scalp Cooling for Chemotherapy Alopecia